Phase 2 (Data)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: PTG-300 (Hepcidin Mimetic) for Polycythemia Vera (PV) - Phase 2 Data
ClinicalTrials.gov (NCT04057040): Hepcidin Mimetic in Patients With Polycythemia Vera
WHAT IS THE CATALYST EVENT?
Phase 2 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and hereditary hemochromatosis.
Polycythemia vera is a myeloproliferative neoplasm characterized primarily by the increased production of red blood cells. Well-established treatment guidelines focus on maintaining hematocrit levels continuously below 45 percent to reduce the risk of thrombotic events. Unfortunately, current treatment options are unable to maintain hematocrit to below the 45 percent target for many patients and may be associated with serious side effects. There are an estimated 100,000 patients with polycythemia vera in the U.S. and approximately 100,000 patients in major EU countries.
Updated by HC
PRTK, Polycythemia Vera (PV), PTG-300 (Hepcidin Mimetic), blood cancer, bone marrow, red blood cells
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post